The global Downstream Processing Market size is expected to reach USD 94.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.0% from 2022 to 2030. The capacity requirements during the development of biologic drugs have changed over the past few years, wherein the demand for manufacturing high-volume products has shifted to developing small-volume, high-potency products. This creates new avenues for single-use technologies. A rise in the utilization of downstream processing techniques for the development of COVID-19 vaccines is a significant factor driving the market. The adoption of small-scale, single-use systems for process development and downstream processing is already high.

Thus, evolutionary changes are expected in the area of single-use technologies for manufacturing small-volume, highly-potent drugs. The development of novel film chemistries, closed systems, automation in clinical-scale single-use systems, and smart sensors are some noteworthy advancements in the field. A rise in applications of downstream processing for the production of biopharmaceuticals is expected to bring growth opportunities to the market. This has also led to an increase in strategic deals and development in the market. For instance, in February 2021, Evozyne, LLC collaborated with a leading rare disorders drug manufacturer for the production and marketing of novel biopharmaceuticals for immune modulation.

Key players are investing in the bioprocessing of vaccines and therapies for COVID-19 to increase their market share. For instance, in May 2022, Lonza and ALSA Ventures are partnering to provide biotech firms with development and manufacturing services. In May 2022, Lonza added Titanium Dioxide-free white hard gelatin capsules to its Capsugel Capsule Line. The new capsule includes an alternative opacifying technology that provides a good masking solution as well as enhanced light protection for the fill formulation. In December 2021, Repligen bought Newton, New Jersey-based BioFlex Solutions. The purchase adds to and enhances Repligen’s single-use fluid management product line, as well as simplifies its supply chain. The integration of BioFlex Solutions strengthens its system offering by further integrating components and assemblies.

Related the Press Release@ Downstream Processing Market Report

Downstream Processing Market Report Highlights

• Chromatography systems accounted for the largest revenue share in 2021 owing to the high adoption of chromatography for biopharmaceutical purification
• The advent of single-use chromatography systems that bring an 80.0% reduction of the use of water and chemicals for buffer has further increased the adoption of chromatography for downstream processing of bio-therapeutics
• Filters are anticipated to grow at a lucrative rate over the forecast period. Efforts undertaken by the key players to develop intelligent membranes for purification & separation is fuelling the market growth
• Purification by chromatography accounted for the largest revenue share as it can be employed across all steps of a downstream process. The technique is also crucial in bioprocessing to obtain pure biologics
• Antibiotic production dominated the market in 2021 owing to the wide use of antibiotics for the treatment of a variety of clinical disorders including infectious diseases and cancer
• A rise in occurrences of antibiotic resistance also propels the industrial-scale development of novel antibiotic candidates
• North America dominated the global market in 2021 owing to the presence of large in-house biopharmaceutical manufacturing facilities
• Asia Pacific will register the fastest CAGR from 2022 to 2030 due to a rise in contract development services in emerging economies